NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.61) by $0.19. View Spring Bank Pharmaceuticals' Earnings History.

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Spring Bank Pharmaceuticals.

5 analysts have issued 12-month target prices for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.70 to $29.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $14.43 in the next twelve months. This suggests a possible upside of 1,001.1% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

News articles about SBPH stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a coverage optimism score of 3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 24,300 shares, a decline of 9.0% from the December 31st total of 26,700 shares. Based on an average trading volume of 253,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company's shares are short sold. View Spring Bank Pharmaceuticals' Current Options Chain.

Some companies that are related to Spring Bank Pharmaceuticals include Zynerba Pharmaceuticals (ZYNE), Aduro BioTech (ADRO), Northwest Biotherapeutics (NWBO), ESSA Pharma (EPIX), NeuBase Therapeutics (NBSE), Paratek Pharmaceuticals (PRTK), OASMIA PHARMACE/ADR (OASM), Marinus Pharmaceuticals (MRNS), CELYAD SA/ADR (CYAD), Millendo Therapeutics (MLND), Chimerix (CMRX), Scpharmaceuticals (SCPH), CV Sciences (CVSI), Oncolytics Biotech (ONCY) and Vaccinex (VCNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Apollo Global Management (APO), Strongbridge Biopharma (SBBP), China Unicom (Hong Kong) (CHU) and Ciena (CIEN).

(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBPH stock can currently be purchased for approximately $1.31.

Spring Bank Pharmaceuticals has a market capitalization of $21.59 million. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

The official website for Spring Bank Pharmaceuticals is http://springbankpharm.com/.

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]